Navigation Links
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/30/2009

PARIS, August 30 /PRNewswire-FirstCall/ --

- SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy. The results of the SEPIA-ACS1/ TIMI-42 were presented today at the plenary session of the Annual European Society of Cardiology congress in Barcelona and simultaneously published online in The Lancet.

Otamixaban is a first in class, rapid onset antithrombotic compound, acting as a direct selective inhibitor of factor Xa. Otamixaban is originating from Sanofi-aventis world-class thrombosis research portfolio and is currently in phase IIb clinical development phase.

"The data show that intermediate dosages of otamixaban may offer substantial reduction in major coronary complications in patients presenting with acute coronary syndrome, with bleeding rate comparable to current therapy," said Dr Marc Sabatine, MD, MPH, an Investigator in the TIMI Study Group and a cardiologist at Brigham and Women's Hospital, Harvard Medical School. "This research is addressing an important medical need, by potentially significantly improving outcomes of ACS patients undergoing PCI while simplifying the treatment pattern of the acute management phase of the disease." he added.

The double-blind phase I
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
2. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
3. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
8. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
9. Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth
10. Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
11. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... SEATTLE, Jan. 31, 2012 /PRNewswire-iReach/ -- Today ... the launch of new last mile postal service delivery ... software. In addition to existing support of multiple global ... cost-effective delivery capabilities to businesses and residences in over ...
... 2012 Vystar Corporation (OTCBB: VYST), the exclusive ... third US and first Chinese patent for its ... five issued patents in the US and abroad that relate ... (Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO ) The new ...
Cached Medicine Technology:Enroute Adds Last Mile Postal Service Delivery Services 2Enroute Adds Last Mile Postal Service Delivery Services 3Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 2Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 3
(Date:12/24/2014)... 2014 The report “Stivarga (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... a drug which is used in the treatment of ... and is also prescribed to patients who suffer from ... approved is a multi-kinase inhibitor and it blocks many ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... one year will be allowed to donate blood in the United ... ban on donations from men who have sex with men. ... release a new draft guidance in early 2015 that would ultimately ... FDA is changing its policy based on data from other countries ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A new, ... Food and Drug Administration. The agency on Tuesday ... for those who are overweight and have at least ... type 2 diabetes or high cholesterol. Patients taking ... a low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... are more likely to start smoking or drinking with ... (ADHD) or conduct disorder, new research suggests. ... the risk of substance use as [these] children approach ... at Cincinnati Pediatric Research Group, which is part of ...
(Date:12/24/2014)... Gluten, a protein found predominately in wheat ... intolerance to gluten, causing side effects that can range ... pain and fatigue. For this reason, Diet Doc created ... safe and fast weight loss while teaching patients how ... reaction. These gluten free diet plans combine the healthiest ...
Breaking Medicine News(10 mins):Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... ... orthodontist, Dr. Inna Gellerman, kicks off holiday season with food drives, toy drives and ... ... , Dr. Inna Gellerman, celebrates the holiday season by participating in various community events, ...
... ... Medtronic founder, joins Dr. Jean Watson to launch The Million Nurse Global ... www.millionnurseproject.org ! . Nurses are uniting to celebrate the 2010 ... and two proposed United Nations Resolutions, together to radiate heart-centered Love and ...
... , ... With over 45 million uninsured in the ... Obama’s plans for health insurance reform in the United States, one ... transcends traditional boundaries. MediBid connects physicians to patients in a free-market ...
... ... has announced that they have added a new line of Natural ... Vitamins are produced on FDA registered and inspected facility operating since ... Medicine’s Nutritional vitamins and supplements make them safe, top quality products. ...
... ... company and "Top 100" Rochester, NY Growth Company, is partnering with AstraZeneca ... for the improved management of hypertension. The partnership program positions community ... a select group of Canadian retail pharmacy participants. , ...
... , AUBURN HILLS, Mich., Dec. ... integrated logistics services and highly customized supply chain solutions ... Worldwide Holdings, Inc. The terms of the transaction are ... , Addison, IL-based NAL is a third-party logistics (3PL) ...
Cached Medicine News:Health News:Long Island Children's Orthodontist, Dr. Inna Gellerman, Celebrates Season of Giving with Holiday Drives and Events 2Health News:The Million Nurse Global Caring Field Project Launches Jan. 1st, 2010 at Noon 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 2Health News:MediBid.com Empowers Physicians to Expand Their Fee for Service Practice with New Online Portal 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 2Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 3Health News:All Alternative Medicine Products LLC. Presents a New Line of Natural Nutritional Supplements and Vitamins 4Health News:PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 2Health News:syncreon Acquires NAL Worldwide Holdings Inc. 3
... comprehensive line of pregnancy tests including rapid ... convenient one-step stick and cassette formats. The ... Easy HCG is a 25 mIU urine ... HCG II provides 25mIU sensitivity for ...
... Wampole Laboratories offers a comprehensive line ... for serum and urine in convenient one-step ... offers 2 testing options. Clearview Easy HCG ... a convenient stick format. Clearview HCG ...
... hemolyzed preparation of whole blood is mixed ... binding cation-exchange resin. During this time, HbAo ... period. a filter separator is used to ... which contains glycohemoglobin. The percent glycohemoglobin is ...
... is the main storage protein for iron. ... shell (apoferritin) composed of heavy and light ... iron oxide and phosphate [1]. Ferritin is ... other body tissues, with major concentrations found ...
Medicine Products: